Physicians are calling on the Biden administration to declare an “emergency” in response to an alarming number of children being hospitalized with respiratory syncytial virus (RSV), yet experts should be demanding that U.S. regulatory agencies look into the connection between the unprecedented surge of this virus during its “off-season” and COVID-19 vaccines.
The Children’s Hospital Association and the American Academy of Pediatrics in a letter to President Joe Biden and Department of Health and Human Services secretary Xavier Becerra warned that “unprecedented levels” of RSV combined with influenza, which disappeared almost entirely from 2020 to 2021, work shortages and the ongoing mental health crises among children are pushing hospitals “to the breaking point.”
Children’s Hospital Association CEO Mark Wietecha and American Academy of Pediatrics CEO Mark Del Monte asked Biden and Becerra for a presidential declaration of an emergency under the Stafford Act or National Emergencies Act and a public health emergency declaration.
“We need emergency funding support and flexibilities along the same lines of what was provided to respond to COVID surges,” they wrote.
Ignoring the fact that declaring a public health emergency would make it easier for pharmaceutical companies such as Pfizer and Moderna to cut corners to get their RSV vaccines to market, the glaringly obvious root cause of the “alarming surge” among children is being entirely ignored.
Attorneys with the Informed Consent Action Network (ICAN), on October 26, sent a letter to CDC director Dr. Rochelle Walensky demanding to know the percentage of children who tested positive for RSV and those who received a COVID-19 vaccine before receiving their diagnosis.
RSV is a common respiratory virus that usually causes mild, cold-like symptoms. Although most people recover in a week or two, it can be very serious in children. In fact, RSV (not COVID-19) is the most common cause of bronchiolitis and pneumonia in U.S. infants.
Cases of RSV are surging and what’s unusually odd is that it’s occurring during the off-season, ICAN reported. RSV usually causes thousands of hospitalizations over fall and winter, but for the second year in a row, experts have seen an unprecedented rise in cases beginning during the summer months.
According to clinical trial data for Moderna’s pediatric COVID-19 vaccine (mRNA-1273), an increased rate of RSV and upper respiratory infections were observed among children who received the vaccine.
For 6- to 23-month-olds, some respiratory tract-related infections were reported with greater frequency within 28 days of receiving Moderna’s COVID-19 vaccine compared to the placebo group. Respiratory infections occurring more frequently in the vaccinated group include croup, RSV and pneumonia.
Events of croup were reported by 1.3% of mRNA-1273 recipients and 0.3% of placebo recipients; RSV by 0.8% of mRNA-1273 recipients and 0.5% of placebo recipients; and pneumonia by 0.2% of mRNA-1273 recipients and no placebo recipients.
For 2- to 5-year-olds, pneumonia events were reported by 0.3% and 0% of mRNA-1273 and placebo recipients, respectively. RSV infection was reported by 0.4% and <0.1% of mRNA-1273 and placebo recipients, respectively.
For 6- to 11-year-olds, RSV was also more frequently reported in the vaccinated group. RSV was reported by 0.3% vs. 0% in the placebo group.
Pfizer’s COVID-19 vaccine (BNT162b2) clinical trial data shows a higher rate of RSV infection was observed in vaccinated children compared to those who received the placebo. Similarly, Pfizer’s pediatric COVID-19 vaccine lists RSV as a serious adverse event among vaccinated children.
Pfizer documents obtained from the U.S. Food and Drug Administration (FDA) by the Public Health and Medical Professionals for Transparency list RSV as an “adverse event of special interest.”
According to ICAN’s press release, the issue was so serious that the FDA’s vaccine advisory panel which “normally cheerleads even the most dangerous vaccine,” acknowledged the correlation and “stressed the importance of continued post-authorization safety surveillance, in particular for … certain respiratory infections (RSV and pneumonia) in the youngest age group, for which imbalances of uncertain clinical significance were observed in the clinical trial.”
The CDC and FDA have ignored the increased rates of RSV infections and its possible connection to COVID-19 vaccines and continue to promote the very vaccine that may actually be contributing to the unprecedented surge in RSV cases.
The CDC recently issued an official health advisory on RSV recommending all children ages 6 months and up receive an influenza and COVID-19 vaccine, while the mainstream media continues to praise Pfizer and Moderna, who are hoping to fast-track their experimental RSV vaccines.